Evidence map›Paper›PMID 39099532›Full record

ArticleChemistryOpen2024

SARS-CoV-2 PL

Sara Protić, Milica Crnoglavac Popović, Nevena Kaličanin, Olivera Prodanović, Milan Senćanski, Jelena Milićević, Kristina Stevanović, Vladimir Perović, Slobodan Paessler, Radivoje Prodanović and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ChemistryOpen, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. SARS-CoV-2 PLChemistryOpen · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Sara ProtićFaculty of Chemistry, University of Belgrade, Studentski Trg 12-16, Belgrade, Serbia.
Milica Crnoglavac PopovićFaculty of Chemistry, University of Belgrade, Studentski Trg 12-16, Belgrade, Serbia.
Nevena KaličaninInstitute of Chemistry, Technology and Metallurgy, University of Belgrade, Njegoševa 12, Belgrade, Serbia.
Olivera ProdanovićInstitute for Multidisciplinary Research, University of Belgrade, Kneza Višeslava 1, Belgrade, Serbia.
Milan SenćanskiLaboratory of Bioinformatics and Computational Chemistry, Institute of Nuclear Sciences Vinca, National Institute of the Republic of Serbia, University of Belgrade, Mike Petrovica Alasa 12-14, Belgrade, Serbia.
Jelena MilićevićLaboratory of Bioinformatics and Computational Chemistry, Institute of Nuclear Sciences Vinca, National Institute of the Republic of Serbia, University of Belgrade, Mike Petrovica Alasa 12-14, Belgrade, Serbia.
Kristina StevanovićLaboratory of Bioinformatics and Computational Chemistry, Institute of Nuclear Sciences Vinca, National Institute of the Republic of Serbia, University of Belgrade, Mike Petrovica Alasa 12-14, Belgrade, Serbia.
Vladimir PerovićLaboratory of Bioinformatics and Computational Chemistry, Institute of Nuclear Sciences Vinca, National Institute of the Republic of Serbia, University of Belgrade, Mike Petrovica Alasa 12-14, Belgrade, Serbia.
Slobodan PaesslerDepartment of Pathology, University of Texas Medical Branch, Galveston, Texas, United States.
Radivoje ProdanovićFaculty of Chemistry, University of Belgrade, Studentski Trg 12-16, Belgrade, Serbia.
Sanja GlišićLaboratory of Bioinformatics and Computational Chemistry, Institute of Nuclear Sciences Vinca, National Institute of the Republic of Serbia, University of Belgrade, Mike Petrovica Alasa 12-14, Belgrade, Serbia.

Funding

Ministry of Science, Technological Development and Innovation of Republic of Serbia 451-03-47/2024-01/200026Ministry of Science, Technological Development and Innovation of Republic of Serbia 451-03-47/2024-01/200053Ministry of Science, Technological Development and Innovation of Republic of Serbia 451-03-47/2024-01/200168Ministry of Science, Technological Development and Innovation of Republic of Serbia 451-03-66/2024-03/200017Ministry of Science, Technological Development and Innovation of Republic of Serbia 451-03-66/2024-03/200042Science Fund of the Republic of Serbia
6 · The paper itself

Abstract

The emergence of drug-resistant viruses and novel strains necessitates the rapid development of novel antiviral therapies. This need was particularly demanding during the COVID-19 pandemic. While de novo drug development is a time-consuming process, repurposing existing approved medications offers a more expedient approach. In our prior in silico screening of the DrugBank database, fidaxomicin emerged as a potential SARS-CoV-2 papain-like protease inhibitor. This study extends those findings by investigating fidaxomicin's antiviral properties in vitro. Our results support further exploration of fidaxomicin as a therapeutic candidate against SARS-CoV-2, given its promising in vitro antiviral activity and favorable safety profile.

Indexed as

Antiviral AgentsDrug RepositioningFidaxomicinSARS-CoV-2Chlorocebus aethiopsComputer SimulationCoronavirus 3C ProteasesCOVID-19 Drug TreatmentHumansMolecular Docking SimulationProtease InhibitorsVero CellsAntiviral AgentsCoronavirus 3C ProteasesFidaxomicinProtease Inhibitorsantiviral therapydrug repurposingfidaxomicinin vitroSARS-CoV-2 PLpro

Identifiers

PMID39099532
PMCPMC11564859

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.